MTSR Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Metsera's net margin of 21.68%. Metsera's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Metsera has a consensus price target of $55.00, signalling upside risk potential of 25.77%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Metsera has higher upside potential than Eli Lilly and, analysts believe Metsera is more attractive than Eli Lilly and.

Metsera has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Metsera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Metsera pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Metsera quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Metsera's net income of -$76.6M is lower than Eli Lilly and's net income of $2.8B. Notably, Metsera's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Metsera is -- versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals has a net margin of -- compared to Metsera's net margin of --. Metsera's return on equity of -- beat Terns Pharmaceuticals's return on equity of --.

Metsera has a consensus price target of $55.00, signalling upside risk potential of 25.77%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.14 which suggests that it could grow by 263.24%. Given that Terns Pharmaceuticals has higher upside potential than Metsera, analysts believe Terns Pharmaceuticals is more attractive than Metsera.

Metsera has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Metsera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Metsera pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

Metsera quarterly revenues are --, which are smaller than Terns Pharmaceuticals quarterly revenues of --. Metsera's net income of -$76.6M is lower than Terns Pharmaceuticals's net income of -$23.9M. Notably, Metsera's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Metsera is -- versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Metsera's net margin of --. Metsera's return on equity of -- beat Viking Therapeutics's return on equity of --.

Metsera has a consensus price target of $55.00, signalling upside risk potential of 25.77%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 185.37%. Given that Viking Therapeutics has higher upside potential than Metsera, analysts believe Viking Therapeutics is more attractive than Metsera.

Metsera has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.744%.

Metsera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Metsera pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Metsera quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Metsera's net income of -$76.6M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Metsera's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Metsera is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ventyx Biosciences has a net margin of -- compared to Metsera's net margin of --. Metsera's return on equity of -- beat Ventyx Biosciences's return on equity of --.

Metsera has a consensus price target of $55.00, signalling upside risk potential of 25.77%. On the other hand Ventyx Biosciences has an analysts' consensus of $12.00 which suggests that it could grow by 283.39%. Given that Ventyx Biosciences has higher upside potential than Metsera, analysts believe Ventyx Biosciences is more attractive than Metsera.

Metsera has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ventyx Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Metsera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ventyx Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Metsera pays -- of its earnings as a dividend. Ventyx Biosciences pays out -- of its earnings as a dividend.

Metsera quarterly revenues are --, which are smaller than Ventyx Biosciences quarterly revenues of --. Metsera's net income of -$76.6M is lower than Ventyx Biosciences's net income of -$27.4M. Notably, Metsera's price-to-earnings ratio is -- while Ventyx Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Metsera is -- versus -- for Ventyx Biosciences. Usually stocks with elevated PS ratios are considered overvalued.